| Variables . | SEER (%) . | Multicenter (%) . |
|---|---|---|
| Total number | 1450 | 349 |
| Age (years) | ||
| Median(range) | 53 (18-99) | 56(19-76) |
| Gender | ||
| Male | 599 (41.3%) | 154 (44.1%) |
| Female | 851 (58.7%) | 195 (55.9%) |
| Race/ethnicity | ||
| White | 1204 (83.0%) | 0 |
| Black | 131 (9.0%) | 0 |
| Others* | 115 (8.0%) | 349 (100%) |
| Grade | ||
| I+II | 78 (5.4%) | / |
| III+IV | 53 (3.7%) | / |
| Unknown | 1319 (90.9%) | / |
| TNM (8th) | ||
| I | 392 (27.1%) | 65 (18.7%) |
| II | 277 (19.1%) | 46 (13.2%) |
| III | 192 (13.2%) | 87 (24.9%) |
| IV | ||
| IVA | 447 (30.8%) | 95 (27.2%) |
| IVB | 25 (1.7%) | 19 (5.4%) |
| IVC | 117 (8.1%) | 37 (10.6%) |
| T category | ||
| T1 | 563 (38.8%) | 93 (26.7%) |
| T2 | 376 (26.0%) | 72 (20.6%) |
| T3 | 359 (24.7%) | 90 (25.8%) |
| T4a | 95 (6.6%) | 43 (12.3%) |
| T4b | 47 (3.2%) | 23 (6.6%) |
| TX | 10 (0.7%) | 28 (8.0%) |
| Tumor size (mm)** | ||
| Median(range) | 24 (1-150) | 20 (3-85) |
| N category | ||
| N0 | 679 (46.8%) | 133 (38.1%) |
| N1a | 224 (15.4%) | 102 (29.2%) |
| N1b | 532 (36.8%) | 92 (26.4%) |
| N1 NOS | 10 (0.7%) | 0 |
| NX | 5 (0.3%) | 22 (6.3%) |
| Number of positive LNs | ||
| Median(range) | 1 (0-73) | 2 (0-42) |
| 0 | 679 (46.8%) | 133 (38.1%) |
| 1-8 | 395 (27.3%) | 104 (29.9%) |
| ≥9 | 358 (24.7%) | 86 (24.6%) |
| Unknown | 18 (1.2%) | 26 (7.4%) |
| M category | ||
| M0 | 1333 (91.9%) | 312 (89.4%) |
| M1 | 117 (8.1%) | 37 (10.6%) |
| Variables . | SEER (%) . | Multicenter (%) . |
|---|---|---|
| Total number | 1450 | 349 |
| Age (years) | ||
| Median(range) | 53 (18-99) | 56(19-76) |
| Gender | ||
| Male | 599 (41.3%) | 154 (44.1%) |
| Female | 851 (58.7%) | 195 (55.9%) |
| Race/ethnicity | ||
| White | 1204 (83.0%) | 0 |
| Black | 131 (9.0%) | 0 |
| Others* | 115 (8.0%) | 349 (100%) |
| Grade | ||
| I+II | 78 (5.4%) | / |
| III+IV | 53 (3.7%) | / |
| Unknown | 1319 (90.9%) | / |
| TNM (8th) | ||
| I | 392 (27.1%) | 65 (18.7%) |
| II | 277 (19.1%) | 46 (13.2%) |
| III | 192 (13.2%) | 87 (24.9%) |
| IV | ||
| IVA | 447 (30.8%) | 95 (27.2%) |
| IVB | 25 (1.7%) | 19 (5.4%) |
| IVC | 117 (8.1%) | 37 (10.6%) |
| T category | ||
| T1 | 563 (38.8%) | 93 (26.7%) |
| T2 | 376 (26.0%) | 72 (20.6%) |
| T3 | 359 (24.7%) | 90 (25.8%) |
| T4a | 95 (6.6%) | 43 (12.3%) |
| T4b | 47 (3.2%) | 23 (6.6%) |
| TX | 10 (0.7%) | 28 (8.0%) |
| Tumor size (mm)** | ||
| Median(range) | 24 (1-150) | 20 (3-85) |
| N category | ||
| N0 | 679 (46.8%) | 133 (38.1%) |
| N1a | 224 (15.4%) | 102 (29.2%) |
| N1b | 532 (36.8%) | 92 (26.4%) |
| N1 NOS | 10 (0.7%) | 0 |
| NX | 5 (0.3%) | 22 (6.3%) |
| Number of positive LNs | ||
| Median(range) | 1 (0-73) | 2 (0-42) |
| 0 | 679 (46.8%) | 133 (38.1%) |
| 1-8 | 395 (27.3%) | 104 (29.9%) |
| ≥9 | 358 (24.7%) | 86 (24.6%) |
| Unknown | 18 (1.2%) | 26 (7.4%) |
| M category | ||
| M0 | 1333 (91.9%) | 312 (89.4%) |
| M1 | 117 (8.1%) | 37 (10.6%) |
*Including American Indian/AK Native, Asian/Pacific Islander/Unkonwn in the SEER database and Chinese in multicenter dataset.
**Twenty-six cases not available in the SEER database.
Abbreviations: TNM, tumor-node-metastasis; LN, lymph node; SEER, Surveillance, Epidemiology, and End Results.
| Variables . | SEER (%) . | Multicenter (%) . |
|---|---|---|
| Total number | 1450 | 349 |
| Age (years) | ||
| Median(range) | 53 (18-99) | 56(19-76) |
| Gender | ||
| Male | 599 (41.3%) | 154 (44.1%) |
| Female | 851 (58.7%) | 195 (55.9%) |
| Race/ethnicity | ||
| White | 1204 (83.0%) | 0 |
| Black | 131 (9.0%) | 0 |
| Others* | 115 (8.0%) | 349 (100%) |
| Grade | ||
| I+II | 78 (5.4%) | / |
| III+IV | 53 (3.7%) | / |
| Unknown | 1319 (90.9%) | / |
| TNM (8th) | ||
| I | 392 (27.1%) | 65 (18.7%) |
| II | 277 (19.1%) | 46 (13.2%) |
| III | 192 (13.2%) | 87 (24.9%) |
| IV | ||
| IVA | 447 (30.8%) | 95 (27.2%) |
| IVB | 25 (1.7%) | 19 (5.4%) |
| IVC | 117 (8.1%) | 37 (10.6%) |
| T category | ||
| T1 | 563 (38.8%) | 93 (26.7%) |
| T2 | 376 (26.0%) | 72 (20.6%) |
| T3 | 359 (24.7%) | 90 (25.8%) |
| T4a | 95 (6.6%) | 43 (12.3%) |
| T4b | 47 (3.2%) | 23 (6.6%) |
| TX | 10 (0.7%) | 28 (8.0%) |
| Tumor size (mm)** | ||
| Median(range) | 24 (1-150) | 20 (3-85) |
| N category | ||
| N0 | 679 (46.8%) | 133 (38.1%) |
| N1a | 224 (15.4%) | 102 (29.2%) |
| N1b | 532 (36.8%) | 92 (26.4%) |
| N1 NOS | 10 (0.7%) | 0 |
| NX | 5 (0.3%) | 22 (6.3%) |
| Number of positive LNs | ||
| Median(range) | 1 (0-73) | 2 (0-42) |
| 0 | 679 (46.8%) | 133 (38.1%) |
| 1-8 | 395 (27.3%) | 104 (29.9%) |
| ≥9 | 358 (24.7%) | 86 (24.6%) |
| Unknown | 18 (1.2%) | 26 (7.4%) |
| M category | ||
| M0 | 1333 (91.9%) | 312 (89.4%) |
| M1 | 117 (8.1%) | 37 (10.6%) |
| Variables . | SEER (%) . | Multicenter (%) . |
|---|---|---|
| Total number | 1450 | 349 |
| Age (years) | ||
| Median(range) | 53 (18-99) | 56(19-76) |
| Gender | ||
| Male | 599 (41.3%) | 154 (44.1%) |
| Female | 851 (58.7%) | 195 (55.9%) |
| Race/ethnicity | ||
| White | 1204 (83.0%) | 0 |
| Black | 131 (9.0%) | 0 |
| Others* | 115 (8.0%) | 349 (100%) |
| Grade | ||
| I+II | 78 (5.4%) | / |
| III+IV | 53 (3.7%) | / |
| Unknown | 1319 (90.9%) | / |
| TNM (8th) | ||
| I | 392 (27.1%) | 65 (18.7%) |
| II | 277 (19.1%) | 46 (13.2%) |
| III | 192 (13.2%) | 87 (24.9%) |
| IV | ||
| IVA | 447 (30.8%) | 95 (27.2%) |
| IVB | 25 (1.7%) | 19 (5.4%) |
| IVC | 117 (8.1%) | 37 (10.6%) |
| T category | ||
| T1 | 563 (38.8%) | 93 (26.7%) |
| T2 | 376 (26.0%) | 72 (20.6%) |
| T3 | 359 (24.7%) | 90 (25.8%) |
| T4a | 95 (6.6%) | 43 (12.3%) |
| T4b | 47 (3.2%) | 23 (6.6%) |
| TX | 10 (0.7%) | 28 (8.0%) |
| Tumor size (mm)** | ||
| Median(range) | 24 (1-150) | 20 (3-85) |
| N category | ||
| N0 | 679 (46.8%) | 133 (38.1%) |
| N1a | 224 (15.4%) | 102 (29.2%) |
| N1b | 532 (36.8%) | 92 (26.4%) |
| N1 NOS | 10 (0.7%) | 0 |
| NX | 5 (0.3%) | 22 (6.3%) |
| Number of positive LNs | ||
| Median(range) | 1 (0-73) | 2 (0-42) |
| 0 | 679 (46.8%) | 133 (38.1%) |
| 1-8 | 395 (27.3%) | 104 (29.9%) |
| ≥9 | 358 (24.7%) | 86 (24.6%) |
| Unknown | 18 (1.2%) | 26 (7.4%) |
| M category | ||
| M0 | 1333 (91.9%) | 312 (89.4%) |
| M1 | 117 (8.1%) | 37 (10.6%) |
*Including American Indian/AK Native, Asian/Pacific Islander/Unkonwn in the SEER database and Chinese in multicenter dataset.
**Twenty-six cases not available in the SEER database.
Abbreviations: TNM, tumor-node-metastasis; LN, lymph node; SEER, Surveillance, Epidemiology, and End Results.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
